Cargando…

Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okabayashi, Shinji, Kobayashi, Taku, Saito, Eiko, Toyonaga, Takahiko, Ozaki, Ryo, Sagami, Shintaro, Nakano, Masaru, Tanaka, Junichi, Yagisawa, Keiji, Kuronuma, Satoshi, Takeuchi, Osamu, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505090/ https://www.ncbi.nlm.nih.gov/pubmed/30704156 http://dx.doi.org/10.5217/ir.2018.00117

Ejemplares similares

Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease
por: Sagami, Shintaro, et al.
Publicado: (2019)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome
por: Toyonaga, Takahiko, et al.
Publicado: (2017)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Inflammatory Bowel Disease in Japan -Is It Similar to or Different from Westerns?-
por: Okabayashi, Shinji, et al.
Publicado: (2020)

Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn’s Disease
por: Asonuma, Kunio, et al.
Publicado: (2023)

Usefulness of colestimide for diarrhea in postoperative Crohn's disease
por: Hojo, Aya, et al.
Publicado: (2022)

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
por: Sagami, Shintaro, et al.
Publicado: (2021)

Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy
por: Hayashi, Ryohei, et al.
Publicado: (2015)

5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis
por: Wada, Haruka, et al.
Publicado: (2023)

Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages
por: Toyonaga, Takahiko, et al.
Publicado: (2016)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study
por: Minami, Naoki, et al.
Publicado: (2015)

Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation
por: Crespo, Elena, et al.
Publicado: (2022)

Tacrolimus for the Treatment of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2015)

Improving IBD outcomes in the era of many treatment options
por: Kobayashi, Taku, et al.
Publicado: (2023)

Aberrant CYP1A1 Induction: Discrepancy of CYP1A1 mRNA and Aryl Hydrocarbon Hydroxylase Activity in Mutant Cells of Mouse Hepatoma Line, Hepa‐1
por: Kikuchi, Hideaki, et al.
Publicado: (1994)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Topical tacrolimus as treatment of atopic dermatitis
por: Furue, Masutaka, et al.
Publicado: (2009)

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus
por: Guo, Zhe, et al.
Publicado: (2023)

Beyond Single Nucleotide Polymorphisms: CYP3A5(∗)3(∗)6(∗)7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients
por: Brazeau, Daniel A., et al.
Publicado: (2020)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
por: Li, Min, et al.
Publicado: (2018)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023)

Preliminary Study of Interaction of Clarithromycin with Tacrolimus in Cats
por: KATAYAMA, Masaaki, et al.
Publicado: (2014)

Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
por: Kim, Jong Man, et al.
Publicado: (2020)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

Novel Single Nucleotide Polymorphisms in Interleukin 6 Affect Tacrolimus Metabolism in Liver Transplant Patients
por: Chen, Dawei, et al.
Publicado: (2013)

The Impact of Single Nucleotide Polymorphisms on the Pharmacokinetics of Tacrolimus in Kidney Allograft Recipients of Northern-West, Iran
por: Jabbari Hagh, Elaheh, et al.
Publicado: (2023)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
por: Mendrinou, Effrosyni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_chv1nscecsot22gsfa588vv62o